{
    "Trade/Device Name(s)": [
        "Randox Cystatin C Level 2",
        "Randox Cystatin C Level 3",
        "Cystatin C Level 2",
        "Cystatin C Level 3"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K121588",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041627"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "JJX"
    ],
    "Summary Letter Date": "June 20, 2012",
    "Summary Letter Received Date": "May 31, 2012",
    "Submission Date": "May 31, 2012",
    "Regulation Number(s)": [
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Quality Control Material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cystatin C"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Cystatin C Level 2 and Level 3 assayed quality control materials for monitoring Cystatin C via immunoturbidimetric assay",
    "Indications for Use Summary": "Intended for in vitro diagnostic use as assayed quality control material for monitoring the precision and accuracy of quantitative determination of human Cystatin C by immunoturbidimetric assays",
    "fda_folder": "Clinical Chemistry"
}